To determine the prognostic potential of baseline plasma biomarkers in patients with cancer undergoing ICI therapy, survival analyses were performed by stratifying patients into high and low groups based on the median plasma concentrations of sPD-L1, sPD-1, and WFDC2. The gene discussed is HOXD13; the disease is cancer.